RESUMO
Fundamento. La biopsia selectiva del ganglio centinela(BSGC) ha reemplazado a la linfadenectomía axilar (LA),como procedimiento de elección, en el estadiaje del cáncerde mama en estadios iniciales y axila clínicamente negativa.El objetivo de este trabajo es comparar la supervivenciaglobal y libre de eventos de aquellas pacientes a lasque se realizó, en el periodo de validación de la técnica,BSGC seguida de LA respecto a las que se practicó BSGCy LA si el ganglio centinela (GC) presentaba metástasis.Material y métodos. Se han incluido 148 pacientes, 81pertenecientes al periodo de validación y 67 al grupo deaplicación clínica. El radiocoloide se administró intraperitumoralmente,obteniéndose imágenes hasta la visualizacióndel GC, posteriormente en la intervenciónquirúrgica se procedió a su identificación y extirpación.Resultados. En el grupo de validación, la eficacia de latécnica ha sido del 92,5%, la sensibilidad del 95,6% y latasa de falsos negativos del 4%. De las 81 pacientes, 75se encuentran libres de enfermedad (92,6%). De las 67pacientes pertenecientes al grupo de aplicación clínica,63 (94%) viven libres de enfermedad. Ninguna pacienteha presentado recurrencia ganglionar axilar.Conclusiones. En la validación de la técnica hemos obtenidounos valores que se hallan dentro de las exigenciasde calidad generalmente aceptadas. Con una mediade seguimiento de 6 años no hemos observado recurrenciaaxilar en ninguno de los dos grupos. No existediferencia estadísticamente significativa en la supervivenciaglobal y libre de eventos entre ambos grupos(AU)
Background. Selective biopsy of the sentinel ganglion(SBSG) has replaced axillary lymphadectomy (AL) asthe procedure of choice in staging breast cancer in itsinitial stages and in clinically negative axilla. The aimof this study is to compare global event-free survival ofthose patients subjected to SBSG followed by AL, duringthe period of validation of the technique, with respectto those subjected to SBSG and AL if the sentinelganglion (SG) showed metastasis.Methods. One hundred and forty-eight patients wereincluded, 81 belonging to the period of validation and67 to the clinical application group. Radiocoloid wasadministered intraperitumorally, obtaining images upuntil the visualisation of the SG; its identification andextirpation were carried out subsequently in the surgicalintervention.Results. The efficacy of the technique in the validationgroup was 92.5%, sensitivity was 95.6% and the rate offalse negatives was 4%. Of the 81 patients, 75 are freeof disease (92.6%). Of the 67 patients belonging to theclinical application group, 63 (94%) are free of disease.No patient has presented axillary ganglion recurrence.Conclusion. In the validation of the technique we obtainedvalues that fall within the demands of generallyaccepted quality. With an average follow up of 6 yearswe did not observe axillary ganglion recurrence in anyof the two groups. There is no statistically significantdifference in global and event free survival between thetwo groups(AU)
Assuntos
Humanos , Feminino , Neoplasias da Mama/patologia , Biópsia de Linfonodo Sentinela , Excisão de Linfonodo , Espectrometria gama , Intervalo Livre de Doença , Recidiva Local de Neoplasia/epidemiologiaRESUMO
BACKGROUND: Selective biopsy of the sentinel ganglion (SBSG) has replaced axillary lymphadectomy (AL) as the procedure of choice in staging breast cancer in its initial stages and in clinically negative axilla. The aim of this study is to compare global event-free survival of those patients subjected to SBSG followed by AL, during the period of validation of the technique, with respect to those subjected to SBSG and AL if the sentinel ganglion (SG) showed metastasis. METHODS: One hundred and forty-eight patients were included, 81 belonging to the period of validation and 67 to the clinical application group. Radiocoloid was administered intraperitumorally, obtaining images up until the visualisation of the SG; its identification and extirpation were carried out subsequently in the surgical intervention. RESULTS: The efficacy of the technique in the validation group was 92.5%, sensitivity was 95.6% and the rate of false negatives was 4%. Of the 81 patients, 75 are free of disease (92.6%). Of the 67 patients belonging to the clinical application group, 63 (94%) are free of disease. No patient has presented axillary ganglion recurrence. CONCLUSION: In the validation of the technique we obtained values that fall within the demands of generally accepted quality. With an average follow up of 6 years we did not observe axillary ganglion recurrence in any of the two groups. There is no statistically significant difference in global and event free survival between the two groups.
Assuntos
Neoplasias da Mama/patologia , Excisão de Linfonodo , Biópsia de Linfonodo Sentinela , Adulto , Idoso , Idoso de 80 Anos ou mais , Axila , Intervalo Livre de Doença , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
Collagen type 1 represents more than 90% of bone matrix. Therefore, quantitation of collagen crosslinks, such as deoxypyridinoline, can provide information on bone resorption degree. An evaluation was made of deoxypyridinoline as well as other bone markets, such as alkaline phosphatase, tartrate resistant acid phosphatase, and hydroxyproline in patients with the diagnosis of osteoporosis. Paget's disease, hyperthyroidism, and chronic renal failure on haemodialysis or not. Deoxypyridinoline levels were significantly increased in patients with osteoporosis, Paget's disease, and hyperthyroidism. Hydroxyproline levels were increased in patients with Paget's disease, and tartrate resistant acid phosphatase was increased in all the entities studied. Deoxypyridinoline can be a more sensitive marker than hydroxyproline, with some advantages, such as its quantitation in a urine specimen and its high bone specificity. In patients with renal failure, tartrate resistant acid phosphatase was the only biochemical marker of bone resorption with increased levels.
